Assessment of Cancer Antigen 15-3 (CA15-3) and Tumor Necrosis Factor-Α (TNF-Α) as Markers in Women with Breast Cancer

Abstract

Background: Breast cancer is still the most common kind of cancer in women, and its incidence is gradually increasing globally. The study aimed to assess cancer antigen 15-3 (CA15-3), and Tumour necrosis factor-α (TNF-α) as markers in women with breast cancer. Materials and methods: This study is case-control design was conducted at National Hospital for Oncology and Hematology in Najaf and AL-Sadder Medical City Hospital. A convenience sampling of 160 samples. The study comprised two groups include 80 patients with breast cancer, 80 healthy controls. Five millilitres of venous blood were collected from every individual in the study consecutively, the blood distributed into: gel tubes (6ml). The blood in tubes is centrifuged for 10 minutes at 3000 rpm. CA 15-3 was measured by utilizing ELFA technology (enzyme-linked fluorescence assay). Tumor necrosis factor-α (TNF-α) were measured by ELISA kit, the biochemical kit used in the study for performed by a company Sun long Biotech Co, Ltd. Results: The results reveal that patients had significantly higher mean CA15-3 levels (30.269±10.666 Ku/l) than controls (16.901±5.742 Ku/l). Regarding TNF-a, the results found that patients had significantly higher mean TNF-a levels (35.510±12.749 Pg/ml) than controls (8.136±3.647 Pg/ml), at statistically significant P. value <0.001. Conclusions: The present study found that TNF-a and CA15-3 levels were higher significantly in women with breast cancer. Furthermore, the results reveal that patients with metastatic BC had had significantly higher mean CA15-3 levels compared to patients with without metastatic BC and controls.